



The effects of omega-3 fatty acid deficiency during development on oxidative fatty acid degradation during maturity in a mouse model of Alzheimer's disease



Ran Furman, Paul H. Axelsen*

Departments of Pharmacology, Biochemistry and Biophysics, and Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

ARTICLE INFO

Article history:

Received 21 October 2018

Received in revised form 25 February 2019

Accepted 5 March 2019

Available online 23 March 2019

Keywords:

Alzheimer's disease

Polyunsaturated fatty acids

Oxidative stress

Neurodegeneration

Docosahexaenoic acid

Arachidonic acid

ABSTRACT

Metabolic conditions during brain development may have long-term consequences on brain metabolism, thereby influencing the risk of neurodegenerative disease in later life. To ascertain the long-term consequences of omega-3 (ω 3) fatty acid deficiency during brain development on oxidative fatty acid degradation in the brain and the development of Alzheimer-like pathology, wild-type (WT) female mice were fed diets that were either replete or deficient in ω 3 fatty acids for 5 weeks. These females were then mated with hemizygous 5xFAD male transgenic (TG) mouse models of Alzheimer's disease, and the progeny were continued on diets that were either ω 3-replete or ω 3-deficient. When the progeny were 6 months of age, they received radiolabeled arachidonic acid (ARA) by intracerebroventricular injection. Five days after these injections, the brains were harvested and oxidative degradation of the radiolabeled ARA was characterized. Among the progeny of female mice on an ω 3-replete diet, TG progeny had lower PSD-95 expression and higher oxidative ARA degradation than WT progeny. Progeny on an ω 3-deficient diet, however, had no significant differences in PSD-95 expression between TG and WT mice, or in the extent of ARA degradation. In TG mice, an ω 3-deficient diet reduced oxidative ARA degradation to a greater extent than in WT mice. The reductions in oxidative ARA degradation occurred even if the progeny of female mice on an ω 3-deficient diet resumed an ω 3-replete diet immediately on weaning. These results demonstrate that dietary ω 3 fatty acid deficiency during development can cause long-term changes in the expression of a synaptic marker and long-term reductions in the rate of ARA degradation in the WT brain, which are not completely alleviated by an ω 3-replete diet after weaning. The elimination of differences between TG and WT mice by an ω 3-deficient diet suggests that mechanisms regulating PSD-95 expression and the oxidative degradation of ARA are related and that the timing of dietary ω 3 intake during development may influence Alzheimer's disease-related pathological changes later in life.

© 2019 Elsevier Inc. All rights reserved.

1. Introduction

Oxidative stress is frequently implicated in the pathogenesis of Alzheimer's disease (AD) (Axelsen et al., 2011). Polyunsaturated fatty acids (PUFAs) are concentrated in the brain and among the most vulnerable compounds to direct chemical damage from oxidative stress. When damaged, they can degrade into highly reactive

oxidative degradation products, including hydroxyalkenals, oxoalkenals, malondialdehyde, and acrolein, causing toxicity through the spontaneous covalent modification of proteins. Proteins modified by Michael addition to 4-hydroxy-2-nonenal (an ω 6 PUFA oxidation product) appear to concentrate around amyloid plaques in AD brains (Furman et al., 2016) and in mouse models of AD (Ellis et al., 2010; Furman et al., 2016), suggesting that amyloid plaques are active centers of oxidative PUFA degradation in AD.

It follows that altering the PUFA content of the brain may alter the pathogenesis of AD. This possibility is supported by observations that a dietary deficiency of docosahexaenoic acid (DHA) and its omega-3 (ω 3) precursors such as α -linolenic acid reduces expression of the postsynaptic marker PSD-95 and lowers cognitive performance in mouse models of AD, whereas dietary ω 3

* Corresponding author at: Department of Pharmacology, 1009C Stellar Chance Laboratories, University of Pennsylvania, Philadelphia, PA 19104-6084, USA. Tel.: +215-898-5000.

E-mail address: axe@pharm.med.upenn.edu (P.H. Axelsen).

supplementation improves cognitive test scores, decreases apoptosis, and lowers amyloid burden (Calon et al., 2004; Lim et al., 2005). However, dietary ω 3 supplementation has not demonstrated any salutary effects in human cases of AD (Freund-Levi et al., 2008; Issa et al., 2006; Plourde et al., 2007; Quinn et al., 2010). One possible explanation for its failure is that ω 3 fatty acids, such as DHA, may have their primary biological role at an early age. This idea is supported by the association observed between low ω 3 consumption during pregnancy and suboptimal neuro-cognitive outcomes in childhood (Hibbeln et al., 2007). Conversely, dietary ω 3 supplementation improved test scores and social behavior in children. A meta-analysis of 34 studies found that ω 3 supplementation improved cognitive development in infants, whereas the effects on cognitive performance in adults are less clear (Heaton et al., 2013).

DHA is the most abundant PUFA in the human brain. Its concentration increases markedly during the third trimester spurt in brain growth, and this increase continues through 8 years of age (Martinez and Mougan, 1998). A corresponding increase of DHA through early childhood has been documented in primates (Miller et al., 2016) and during rodent development (Green et al., 1999; Green and Yavin, 1996). A failure to accumulate DHA during gestation has been shown to cause physical and behavioral abnormalities in rodents, such as delayed cell migration, reduced proliferation in the dense cortical plates, CA1 region, and the dentate gyrus (Tang et al., 2016; Yavin et al., 2009), as well as an increase in GABA-antagonist-induced heart rate changes, and enhanced depressive-like behavior (Chen and Su, 2013; Tang et al., 2016; Yavin et al., 2009). An elevated ω 6/ ω 3 PUFA ratio in the rodent diet impairs neocortical neurogenesis in the offspring and increases anxiety-related behavior in adulthood (Sakayori et al., 2016). Even if brain DHA concentrations are restored on a DHA-containing diet, concentrations in the brain are slower to normalize than in other organs and abnormalities persist well after DHA concentrations return to normal (Lozada et al., 2017).

DHA may be synthesized by the liver from an ω 3 PUFA precursor, α -linolenic acid (Pauter et al., 2017). However, the capacity of endogenous synthetic mechanisms to produce this precursor is limited, and therefore, the availability of DHA is critically dependent on dietary ω 3 PUFA intake (Rapoport et al., 2010). Moreover, dietary ω 3 deficiency promotes the formation of otherwise uncommon ω 6 PUFAs (Axelsen et al., 2016), which alters the ratio of ω 6 to ω 3 PUFAs in the brain and may lead to neurological disorders (Husted and Bouzinova, 2016; Simopoulos, 2016).

Isotopically labeled forms of arachidonic acid (ARA— U - ^{14}C -ARA and U - ^{13}C -ARA) (Lee et al., 2017) have been used in transgenic (TG) mouse models of AD and in the human brain to show that oxidative chemical degradation of ARA is accelerated in the immediate vicinity of amyloid plaques (Furman et al., 2016) and that oxidative ARA degradation products accumulate in the cortical tissue of AD brains (Furman et al., 2018). In this work, U - ^{14}C -ARA was introduced by intracerebroventricular (ICV) injection and the rate of oxidative ARA degradation in the brain was characterized by examining the distribution of ^{14}C activity among oxidative degradation products. The effects of maternal dietary ω 3 deficiency on the rate of oxidative ARA degradation in their progeny were examined in WT mice and in a mouse model of AD known to exhibit evidence of increased oxidative stress.

Results show that a dietary ω 3 deficiency during development (i.e., gestation and weaning) has persistent effects in the brains of adult progeny, reducing the oxidative degradation of ARA and altering the expression of a synaptic marker. Restoring ω 3 PUFAs in the diet after weaning partially restores brain DHA concentrations, but other effects of ω 3 deficiency during development persist into adulthood.

2. Materials and methods

2.1. Reagents

PSD-95 antibodies were purchased from Antibodies Incorporated (Davis, CA). Donkey anti-mouse antibodies were purchased from Santa Cruise Biotechnology (Dallas, TX). Unlabeled ARA was purchased from Nu-Check Prep Inc. (Elysian, MN). Uniformly labeled [U - ^{14}C]-ARA was prepared as described by (Lee et al., 2017); d 5-DHA was purchased from Cayman Chemicals (Ann Arbor, MI). All other chemicals were purchased from Fisher Scientific (Pittsburgh, PA).

2.2. Animals and diets

Hemizygous transgenic 5x*FAD* (TG) and wild-type B6SJL/J (WT) mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Mice were fed *ad libitum* either an AIN-93G purified rodent diet or a custom formulated low ω 3 diet, with compositions as listed in Table 1. All experimental procedures and animal care were in compliance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.

Female WT mice were maintained on ω 3-replete or ω 3-deficient diets for 5 weeks before being mated with hemizygous TG males. The progeny were genotyped on weaning and divided into 3 groups according to the experimental scheme illustrated in Fig. 1: all of the progeny on an ω 3-replete diet were continued on the same diet (the “NN” group). Among the mice on an ω 3-deficient diet, half of the progeny were continued on an ω 3-deficient diet (“LL” group), whereas the other half were given an ω 3-replete diet (“LN” group). All tested animals were first-litter pups, to avoid parity effects (Ozias et al., 2007).

2.3. Intracerebroventricular injections

[U - ^{14}C]-ARA stock was stored in ethanol at -80 °C. Immediately before use, the ethanol was evaporated and the residue was resuspended in 90% phosphate-buffered saline (PBS)/10% dimethyl sulfoxide by volumes. ICV injections of 0.3–0.5 μ Ci were performed as described previously (Furman et al., 2016). Five days after injection, animals were sacrificed by CO_2 asphyxiation and brains were removed and dissected on dry ice within 3 minutes after death.

Table 1

Composition of the ω 3-replete and ω 3-deficient diets (all values are grams per kilogram)

Component	ω 3-replete (#101093)	ω 3-deficient (#101094)
Casein	200	200
Sucrose	99.98	99.98
Cornstarch	150	150
Dextrose	200	200
Maltose dextrin	150	150
Cellulose	49.5	49.5
<i>tert</i> -Butyl-hydroquinone	0.02	0.02
Salt mix #210025	35	35
Vitamin mix #310025	10	10
L-Cystine	3	3
Choline bitartrate	2.5	2.5
Fatty acids		
Myristic	11.6	12.8
Palmitic	8.2	8.4
Stearic	8.8	9.4
Oleic	5.3	4.1
Linoleic	26.4	26.4
Linolenic	4.4	0
Octanoic	3.7	4.1
Decanoic	3.2	3.6
Lauric	28.3	31.2




Fig. 1. Experimental scheme. There were 5 stages in the experimental scheme. Stage 1: Female WT mice, fed either an ω 3-replete or ω 3-deficient diet for 5 weeks, were mated with hemizygous male TG mice. Stage 2: On weaning, the progeny of female mice on an ω 3-deficient diet were either continued on an ω 3-deficient diet or switched to an ω 3-replete diet for 6 months, whereas the progeny of female mice on an ω 3-replete diet were continued on an ω 3-replete diet for 6 months. This protocol yielded WT and TG mice in 3 different “diet groups” designated NN, LN, and LL. Five days before brain tissue was harvested, U- 14 C-ARA was introduced by ICV injection. Stage 3: Three brain regions from each mouse were dissected, extracted, and fractionated as described in [Materials and methods](#). Stage 4: The middle/upper and the lower phases of the Bligh-Dyer extract were fractionated according to solubility. Stage 5: The M fraction was subfractionated by reversed-phase (RP) HPLC. Typical products identified by mass spectrometry in each subfraction are indicated. Abbreviations: Cb, cerebellum; Cx, cortex; Hc, hippocampus; BD_{MU}, middle/upper phase of the Bligh-Dyer extract; BD_L, lower phase of the Bligh-Dyer extraction; HPLC, high-performance liquid chromatography; Sp, protein-depleted supernatant from the BD_{MU} phase; Pr, proteins precipitated from the BD_{MU} by TCA; W, water-soluble fraction from the BD_L phase; M, methanol-soluble fraction from the BD_L phase; TCA, trichloroacetic acid; ICV, intracerebroventricular; TG, transgenic; WT, wild type.

Tissue samples (~20 mg) from the hippocampus (Hc), parietal cortex (Cx), and cerebellum (Cb) were separated, weighted, and transferred to glass vials (MicroSolv Technology Corp., Eatontown, NJ).

2.4. Lipid extraction and protein precipitation

Bligh-Dyer extractions (BDx) were performed as described by (Furman et al., 2016). Tissues were placed in 760 μ L of BDx monophasic (400 μ L methanol, 200 μ L dichloromethane, and 160 μ L of 5 mM ammonium acetate in water) and tip-sonicated (F60 Sonic Dismembrator; Fisher Scientific). The extract was transferred to a 15-mL glass tube (Fisher Scientific), and an additional aliquot of 760 μ L monophasic was added for each 5 mg of tissue beyond 5 mg (i.e., 2 additional 760 μ L aliquots of monophasic would be added to a 17-mg sample). Then, for each 760 μ L aliquot of monophasic, 200 μ L of dichloromethane and 160 μ L of 5 mM ammonium acetate in water were added to break the monophasic (i.e., a 17-mg sample of tissue would ultimately be mixed in 3 \times 760 μ L monophasic plus 3 \times 200 μ L dichloromethane plus 3 \times 160 μ L of 5 mM ammonium acetate in water). The tube was vortexed for 1 minute and centrifuged at low speed for 2 minutes to separate the phases.

The lower phase of the BDx (BD_L) was removed, evaporated under nitrogen, resuspended in 750 μ L of 85% methanol and 250 μ L of 2 M sodium hydroxide, and saponified for 1 hour at 80 $^{\circ}$ C. Following saponification, samples were acidified with 150 μ L of 5M HCl, dried under nitrogen, and dissolved in methanol (the M fraction). The remaining white residue was dissolved in 200 μ L of water (the W fraction).

The middle and the upper phases of the BDx (BD_{MU}) were vortexed, and a sample was withdrawn for radioactivity measurement. The remainder was dried under nitrogen, resuspended in 300 μ L of water, and transferred into a polypropylene bullet tube. The original tube was washed with 300 μ L of acetone and added to the aqueous

suspension (total 600 μ L of acetone:water). Proteins were precipitated by adding 150 μ L of 65% trichloroacetic acid (TCA) in acetone to yield a final TCA concentration of 13%. Following overnight incubation at -20 $^{\circ}$ C, samples were centrifuged at 13,000 g for 12 minutes at 4 $^{\circ}$ C. The supernatant (Sp) was transferred to a new bullet tube (~600 μ L), whereas the protein pellet (Pr) was subjected to 2 wash cycles in 500 μ L cold acetone. Following each wash, the Sp was collected and added to the Sp. The final pellet was air dried and resuspended in 300 μ L of cold Tris-buffered saline with Tween 20 (20 mM Tris, 150 mM NaCl, and 0.1% Tween 20, pH 7.4) supplemented with protease inhibitors (phenylmethylsulfonyl fluoride 0.2 mM, leupeptin 1 μ g/mL, and aprotinin 1 μ g/mL). The suspension was agitated with a tip sonicator for 1 minute. Protein concentrations in the Pr and Sp were measured by bicinchoninic acid assay (Thermo Fisher, Waltham, MA). The amount of protein in the Pr was >9-fold higher than that in the Sp.

2.5. Radioactivity measurements and data analysis

An aliquot of the BD_{MU} and each of the 4 fractions (W, M, Sp, and Pr) was mixed with 4 mL Ecolite scintillation fluid (MP Biomedicals, Santa Ana, CA) in a 5-mL scintillation vial (Lake Charles Manufacturing, Lake Charles, LA) and counted for 1 minute in the LS 6500 Multipurpose Scintillation Counter (Beckman Coulter, Brea, CA) operating in auto-DPM mode. All results are reported in disintegrations-per-minute (DPM). A scale factor, f_L , was calculated to correct for activity losses incurred during processing of the BD_{MU} according to

$$f_L = \frac{A_{BD_{MU}} \cdot V_{BD_{MU}}}{A_{Sp} \cdot V_{Sp} + A_{Pr} \cdot V_{Pr}}$$

where A is the activity per unit volume and V is the volume of the BD_{MU}, Sp, and Pr fractions. Values of f_L ranged from 1.0 to 1.6.

Therefore, the total activity in the 4 fractions of each sample (A_T) was given by

$$A_T = (A_{Sp} \cdot V_{Sp} + A_{Pr} \cdot V_{Pr})f_L + A_{BD_L} \cdot V_{BD_L}$$

Results for each fraction are reported as % of total activity in the Pr, Sp, M, and W fractions.

2.6. PSD-95 determinations

Proteins were isolated from the BD_{MU} using TCA precipitation. A portion of each Pr fraction was loaded onto a Tris-Tricine 16.5% PAGE gel (0.225 μ g protein/well), electrophoresed, and transferred to a 0.2 μ m nitrocellulose membrane using a Western transfer cassette (Mini Trans-Blot Cell; BIORAD, CA). The membrane was blocked overnight at 4 °C with 5% fat-free milk in PBS (137 mM NaCl, 12 mM phosphate, 2.7 mM KCl, pH 7.4), washed with PBST (PBS + 0.1% Triton X-100), and incubated overnight at 4 °C with PSD-95 antibodies (1:1000) in 2% fat-free milk in PBST. Blots were washed 3 times in PBST and then incubated with horseradish peroxidase donkey anti-mouse antibody (1:10,000) in 2% fat-free milk in PBST for 30 minutes at room temperature, followed by 30 minutes at 37 °C. For detection, all nitrocellulose membranes were incubated with WEST Femto enhanced chemiluminescent horseradish peroxidase substrate (Thermo Fisher) for 5 minutes, imaged with a multi-application gel system (Syngene PXi, Frederick, MD), and densitometrically quantified with image J (National Institutes of Health, Washington DC).

2.7. Chromatography of radioactive samples

Saponified M fractions from the BD_L were injected onto a 4.6 \times 150 mm XDB-C18 column (Agilent, Santa Clara, CA) with a mobile-phase gradient running at 0.35 mL/min. Solvent A was 60% acetonitrile, 40% H₂O, and 0.1% formic acid; solvent B was 100% acetonitrile and 0.1% formic acid. The mobile-phase composition was changed linearly from 30% to 100% B over 55 minutes and held at 100% B for 9 minutes. Column performance was characterized by the analysis of effluent from nonradioactive samples with an ABI 4000 mass spectrometer (Toronto, Canada) operating in negative ion multiple reaction monitoring (MRM) mode as described previously (Furman et al., 2016). Subfractions (6–12 mL) were collected over 60 minutes, and the radioactivity in each subfraction was divided by the total radioactivity that eluted from the column.

2.8. Quantitative PUFA analysis

WT mice were euthanized by CO₂ asphyxiation at 6 months of age. Samples (~20 mg) of Cx and Cb were excised, rapidly frozen on dry ice, transferred to autosampler vials, and weighed. To each sample, 10 μ L of 100 μ M butylated hydroxytoluene, 10 μ L of 10 mM *d5*-DHA in methanol, and 10 μ L of 10 mM *d8*-ARA in methanol were added as internal standards. The sample was tip-sonicated, and BD_x was performed as described previously. BD_L from each sample was saponified, dried, and dissolved in methanol as described for radioactive samples mentioned previously.

The saponified BD_L from each sample was analyzed by injecting a 20 μ L volume onto a 1 \times 250 mm Zorbax 300SB 5 μ m C18 column (Agilent). Solvent A was 8% acetonitrile, 92% water, and 0.1% formic acid. Solvent B was 100% acetonitrile and 0.1% formic acid. The mobile phase was pumped at 100 μ L/min as the composition was changed linearly from 8% to 80% solvent B over 25 minutes and then held at 80% B. The eluent was alkalized post-column with 0.15 M ammonium hydroxide in methanol flowing at 50 μ L/min before being introduced via electrospray ionization into an ABI 4000 mass

spectrometer (SCIEX, Toronto, Canada) operating in negative ion mode. The declustering potential was –70V, the ionization energy was –4500V, and the drying gas temperature was 200 °C. The collision gas was nitrogen at 7 psi, and the collection time for each transition in MRM liquid chromatography tandem mass spectrometry methods was 100 ms. Results are reported as the ratio of integrated MRM signals from analyte to internal standard; i.e., DHA/*d5*-DHA and ARA/*d8*-ARA per gram wet tissue. There was no significant difference in PUFA concentrations in the Cx and Cb, so the results from both regions were combined.

2.9. Statistical analysis

Statistical analysis was performed with SigmaPlot (Systat Software Inc) using one-way analysis of variance for single variants, 2-way analysis of variance for multiple variants, and the Holm-Sidak method for *post hoc* testing. The latter has the potential to indicate a lower *p*-value than would be obtained when applying a more stringent test, such as Bonferroni, to comparisons that are independent. Data are presented as means of at least 4 biological repeats, and all error bars represent standard errors of the means.

3. Results

DHA and ARA concentrations were measured at 6 months of age in the cortical brain tissue of WT progeny of mice fed on NN, LN, and LL diets. Significant amounts of both PUFAs were only recovered from the BD_L (data not shown). WT animals in the NN group had 60 nmoles/gm of DHA in their cortical brain tissue, consistent with prior results from GC-MS (Fig. 2 and Table S1) (Axelsen and Murphy, 2010). DHA concentrations declined by 53% (to 28 nmoles/gm) in the LL group compared with the NN group. The DHA concentration in the LN group (48 nmoles/gm) was not significantly different from the concentrations in the LL or NN group, suggesting that DHA concentrations were not fully replenished in the brain after 6 months on an ω 3-replete diet. ARA concentrations were similar in all the diet groups (~60 nmoles/gm).

The effects of dietary ω 3 deficiency on the expression of PSD-95 (a synaptic marker) were assayed in the cortical brain tissue of WT and TG mice. This marker is known to be lower in mouse models of AD (Oakley et al., 2006), and indeed, it was found to be 30% lower among TG mice in the NN group (the TG/WT ratio was 0.7, Fig. 3 and




Fig. 2. An ω 3-deficient diet reduces DHA concentrations in offspring. The data represent the mean and standard error of 8 samples from 4 animals. Numerical results are provided in Table S1. ** indicates a difference with *p* < 0.01 by *t*-test. NN—an ω 3-replete diet throughout development and thereafter for 6 months; LN—an ω 3-deficient diet during development and then switched to an ω 3-replete diet; LL—an ω 3-deficient diet throughout. Abbreviations: ARA, arachidonic acid; DHA, docosahexaenoic acid.




Fig. 3. An ω 3-deficient diet reduces differences between WT and TG mice in hippocampal PSD-95 expression. Each panel represents a different diet group, and results are normalized to 1.0 for results from WT brains. The number of animals represented by each vertical bar is indicated. * indicates a difference with $p < 0.05$ by the t -test. Because Western blots for each diet group were done on different nitrocellulose membranes, valid comparisons may only be made within each diet group. NN—an ω 3-replete diet throughout development and thereafter for 6 months; LN—an ω 3-deficient diet during development and then switched to an ω 3-replete diet; LL—an ω 3-deficient diet throughout. Abbreviations: TG, transgenic; WT, wild type.

Table S2). In contrast, the TG/WT ratio was indistinguishable from 1.0 in the LN and LL diet groups.

The consequences of dietary ω 3 deficiency on oxidative PUFA degradation were explored by examining the fate of ICV-injected [14 C]-ARA. Because the radiolabel was uniformly distributed along the hydrocarbon chain of ARA, measurements of radioactivity were quantitative with respect to the fate of ARA-derived carbon atoms. Each mouse received 0.3–0.5 μ Ci of [14 C]-ARA via ICV. Cx, Cb, and Hc regions of the brains were harvested after 5 days, and samples from each region were processed as outlined in Fig. 1. The 14 C activity recovered from the Pr and Sp fractions of the BD_{MU} and from the W and M fractions of the BD_L are shown in Fig. 4 and Table S3.

Most (50%–70%) of the 14 C activity was recovered in the M fraction of the saponified BD_L . This fraction includes esterified ARA species, such as phospholipids and triglycerides (Furman et al., 2016). 18%–45% of the activity was recovered in the Sp fraction of the BD_{MU} . This fraction includes unesterified oxidized ARA species, such as isoprostanes and most likely any intermediates of beta oxidation (Furman et al., 2018). 5%–15% was recovered from the Pr fraction. Because this fraction mainly includes proteins and the 14 C activity was originally only in ARA, we infer that this activity was most likely due to proteins that have been covalently modified by chemically reactive PUFA oxidation products, such as 4-hydroxy-2-nonenal, malondialdehyde, and acrolein. There were no statistically significant differences in the distribution of 14 C activity between diet groups, brain regions, or genotypes, suggesting that the distribution of 14 C activity into these fractions was not significantly changed by ω 3 deficiency in the maternal diet.

The distribution of 14 C activity within the M fraction of the BD_L was separated by high-performance liquid chromatography into 6 sub-fractions according to retention time (Fig. 1 and Fig. S1). These sub-fractions have been previously characterized by mass spectrometry with respect to the classes of compounds they contain (Furman et al., 2016). Subfraction I contains early-eluting extensively oxidized polar degradation products, such as isoprostanes, subfraction II contains oxidation products of intermediate polarity, such as hydroxyeicosatetraenoic acids, and subfraction V contains intact ARA.

In the NN diet group, the amount of 14 C activity recovered as intact ARA (subfraction V) was similar in the Cb, Cx, and Hc of WT

animals (~55%), suggesting that extent of ARA degradation does not differ greatly across the brain regions in WT animals on an ω 3-replete diet (Fig. 5, lower panels, Fig. S1, and Table S4). However, subfraction V activity was significantly lower in the Cx of TG animals in the NN diet group, consistent with previously published results showing that the oxidative degradation of ARA is increased in TG animals (Anderson et al., 1987). Subfraction V activity also tended lower in the Cb and Hc of TG animals, but results did not meet criteria for statistical significance.

There were numerous statistically significant differences between diet groups in subfractions I and V of fraction M (Fig. 5). In general, subfraction V activity was frequently greater in the LN and LL diet groups than NN, whereas the activity in subfraction I was frequently lower. These results—an increase in subfraction I compensated for by a reduction in subfraction V—indicate that dietary ω 3 deficiency tends to reduce oxidative ARA degradation. This finding in the LN diet group has special significance in that ω 3 deficiency only during development was sufficient to reduce ARA degradation in mature animals, even despite months of an ω 3-replete diet. The reduction of ARA degradation was evident in both WT and TG mice and both Cx and Hc brain regions. It was also evident in the Cb of TG mice, but not in WT mice. There were relatively small amounts of activity recovered in subfractions III, IV, and VI and no significant differences in recovered activity between diet groups.




Fig. 4. Changes in the ω 3 content of diets do not significantly change the distribution of 14 C-ARA across fractions. Extracts from the Cb, Cx, and Hc of WT and TG mice in the 3 diet groups were separated into 4 fractions as described in Fig. 1. The radioactivity in each fraction is expressed as a percentage of the total in all fractions for each sample. There were no statistical differences between groups. The data represent the mean and standard error of results from the number of animals indicated at the base of the bars in the bottom panel. Abbreviations: Cb, cerebellum; Cx, cortex; Hc, hippocampus; BD_{MU} , middle/upper phase of the Blish-Dyer extract; BD_L , lower phase of the Blish-Dyer extraction; Pr, protein-rich pellet from the BD_{MU} ; Sp, protein-depleted BD_{MU} supernatant; W, water-soluble, methanol-insoluble material in the BD_L ; M, methanol-insoluble material in the BD_L ; TG, transgenic; WT, wild type.




Fig. 5. A low ω 3 diet reduces ARA degradation in subfractions of the methanol-soluble (M) fractions. M fractions were separated by HPLC into the 6 subfractions illustrated in Fig. 1 (see also Figure S1B). The activity in each subfraction is expressed as a percentage of the total in all 6 subfractions. Most of the activity was found in fractions I (earliest eluting, most polar), II (monooxygenated species), and V (unmodified ARA). Blue barbell symbols indicate results for which the difference is significant with $p < 0.05$. Red barbell symbols indicate results for which the difference is significant with $p < 0.01$. Abbreviations: ARA, arachidonic acid; Cb, cerebellum; Cx, cortex; Hc, hippocampus; HPLC, high-performance liquid chromatography; TG, transgenic; WT, wild type.

4. Discussion

These results demonstrate that a dietary ω 3 PUFA deficiency during development has long-term effects on brain metabolism and synaptic proteins that persisted into adulthood, even if an ω 3-replete diet is provided after weaning. Unexpectedly, the effects of ω 3 deficiency included a reduction in the oxidative degradation of ARA in both WT and TG progeny and normalization of the relatively low expression of PSD-95 in adult TG mice.

These results were unexpected because dietary ω 3 supplementation—not deficiency—in adult TG mice has been found to preserve synaptic markers and reduce AD-like pathology (Calon and Cole, 2007; Calon et al., 2004; Lim et al., 2005). Maternal dietary ω 3 PUFA deficiency has been shown in other systems to cause delayed cell migration (Yavin et al., 2009), impaired neurogenesis (Tang et al., 2016), reduced expression of synaptic proteins (Lozada et al., 2017), and increased appetite (Mathai et al., 2004). Restoration of ω 3 PUFA levels in the rodent and monkey brain after a period of dietary deficiency requires weeks to months (Connor et al., 1990; Kudas et al., 2002; Moriguchi et al., 2001; Xiao et al., 2005; Youyou et al., 1986). Therefore, it was expected that dietary ω 3 deficiency during gestation would have effects that persisted into adulthood,

but the nature of the effects observed in these experiments—a reduction of oxidative PUFA degradation—was not expected.

To date, only a very limited number of studies have addressed the link between maternal diet and neurodegenerative disorders in adults. (Maekawa et al., 2017) revealed that maternal DHA depletion elicited schizophrenia-like phenotypes in mature mice through hypermethylation of the RXR and PPAR promoters, (Weiser et al., 2016b) demonstrated that DHA supplementation during gestation alleviated autism-like behavior in the progeny, and (Lozada et al., 2017) showed that maternal ω 3 deficiency elicited long-term effects on cognition that could not be reversed by repletion at an older age. The biochemical role of ω 3 PUFAs in the brain is not known, but it is widely recognized that they are essential for brain development (Lauritzen et al., 2016; Morse, 2012; Weiser et al., 2016a) and that their concentrations increase markedly in the human (Ballabriga and Martinez, 1978; Martinez and Mougan, 1998) and rat brain (Sinclair and Crawford, 1972) late in gestation. This concentration increase coincides with a correspondingly marked increase in brain mass and the development of synaptic connections (Dobbing and Sands, 1979; Stiles and Jernigan, 2010). ω 3 deficiency in adult TG mice has been shown by others to aggravate an AD-related change in postsynaptic markers, including PSD-95, and these effects could be reversed by ω 3 supplementation (Calon et al., 2004). Indeed, dietary ω 3 PUFA supplementation increases oxidative lipid degradation in rat synaptosomal membranes (Salvati et al., 1993).

It has been reported that ω 3 deficiency during adulthood reduces PSD-95 concentrations in the brain and that this effect could be ameliorated by ω 3 supplementation (Calon et al., 2004; Lozada et al., 2017). However, the experimental results reported herein suggest that ω 3 deficiency during development may not be ameliorated by ω 3 supplementation. This difference may have its basis in a need for ω 3 PUFAs during neuronal development, but not for neuronal “maintenance” during adulthood. In other words, the effect of ω 3 deficiency during neuronal development may be irreversible, whereas its effect during adulthood may be reversible. This explanation is consistent with the findings of Lozada et al., who showed that maternal ω 3 depletion alters hippocampal synaptic protein expression, spatial learning, and memory—effects that can be reversed by providing ω 3 PUFAs at 3 weeks of age, but not at 2 and 4 months (Lozada et al., 2017) and that may be mediated by the pharmacological effects of oxidative ARA degradation products. Although we observed no significant changes in the Sp fraction, where we would expect to find pharmacologically active eicosanoids, the amount of activity in this fraction was small and the compounds can be potent, so that pharmacologically significant changes may have escaped detection. For example, an F2 isoprostane caused memory deficits, an increase in tau phosphorylation, an activation of the cyclin kinase 5 pathway, and neuroinflammation in mice (Lauretti and Pratico, 2017).

Oxidative ARA degradation may occur via enzyme-mediated or so-called “chemically” mediated nonenzymatic mechanisms, and both mechanisms of ARA degradation have been documented in patients with AD. For example, an increase in 5, 12, and 15 lipooxygenase activity has been associated with tau pathology, synaptic integrity, β secretase expression, and mitochondrial damage during oxidative stress in TG mice, as well as in people with mild cognitive impairment and AD. (Chu et al., 2012; Giannopoulos et al., 2013; Pallast et al., 2009) In contrast, compounds such as 4-hydroxynonenal are well documented in the brain and are believed to originate solely from the chemical degradation of ω 6 PUFAs (Lee and Blair, 2000; Lin et al., 2005; Zhang et al., 2003). The analyses performed herein do not distinguish between these mechanisms of ARA degradation. However, the products of enzyme-mediated ARA degradation are likely to be nonesterified

and consequently more likely to partition into the BD_{MU} (Furman et al., 2018). Analysis of BD_{MU} fractions revealed no clear differences attributable to diet (Fig. 4). The statistically significant results of this study were all found in subfractions of methanol-soluble material in the BD_L, suggesting that diet exerted its principal effects on chemically mediated ARA degradation.

A possible explanation for decreased ARA degradation in the setting of ω 3 PUFA deficiency is that ω 3 deficiency is likely to decrease DHA degradation, which, in turn, reduces the production of toxic or inflammatory DHA-derived oxidation products that activate antioxidant and radical-scavenging mechanisms. Because A β -mediated oxidative stress appears to precede neuronal loss in APP^{swe}/hPS1 Δ E9 TG mice (Xie et al., 2013), the ability of an ω 3-enriched diet to reduce neuronal damage may be mediated by ω 3-derived activators of the cellular antioxidant response (Leonardi et al., 2005; Salvati et al., 1993; Schebb et al., 2014). This explanation is supported by data showing that regulators of oxidative stress, such as Nrf2 and Gpx4, are specifically activated by oxidative ω 3 degradation products, such as J3 isoprostanes, hydroxyhexenal, and hydroxyl-DHA (Cao et al., 2004; Groeger et al., 2010; Gruber et al., 2015; Zhang et al., 2014). Nrf2 is located primarily in the cytoplasm where it cannot induce the expression of antioxidant proteins (Ramsey et al., 2007). However, oxidative DHA degradation products cause the translocation of Nrf2 into the nucleus where it can induce an antioxidant response and mitigate oxidative degradation (Cao et al., 2004). Consequently, a reduction in oxidative DHA degradation products could render the mechanisms that protect ARA relatively unresponsive to oxidative stress and thereby result in increased oxidative ARA damage.

PSD-95 is immunoreactive material associated with the postsynaptic density of neuronal glutamatergic receptors; it is frequently used as a surrogate measure of synaptic health or abundance (Hunt et al., 1996; Savioz et al., 2014; Won et al., 2017). PSD-95 expression was significantly affected by both diet and genotype in these experiments. TG animals in the NN diet group had significantly lower PSD-95 expression than WT animals on the same diet, a finding that reproduces results previously reported by others for this mouse model of AD (Oakley et al., 2006). PSD-95 expression in TG animals normalized in the LN and LL diet groups, compared with WT animals in the same diet groups. This finding echoes the normalization of PSD-95 expression in the same mouse model with bexarotene treatment (Mariani et al., 2017) and normalization after the implantation of mesenchymal human stem cells into the animal brain (Kim et al., 2018). Because PSD-95 determinations are relative, not absolute, it remains unclear whether the normalization in PSD-95 expression in among TG mice in the LN and LL diet groups is due to greater expression of PSD-95 under these conditions or due to reduced expression of PSD-95 among WT mice in the LN and LL diet groups.

The mechanism by which diet, genotype, and PSD-95 expression are linked is not known. One or more protein components of the postsynaptic density binds A β peptides, and it has been suggested that this interaction may mediate some of the neurotoxic effects attributed to some forms of these peptides (Savioz et al., 2014). WT mice on a diet enriched in an ω 6 PUFA (ARA) for 12 weeks exhibited a marked reduction in PSD-95 expression—an effect that was partially reproduced by the ICV injection of A β ₄₂ (Thomas et al., 2017). Within the 5x3DAD model of AD, PSD-95 expression declines with age and to a greater extent in TG than in WT animals (Neuman et al., 2015; Shao et al., 2011).

5. Conclusion

This work demonstrates that maternal ω 3 deficiency has an effect on the rate of oxidative ARA degradation in their progeny

that persists into adulthood and that this effect is in an unexpected direction: ω 3 deficiency reduces oxidative ARA degradation. These effects are similar in WT and TG mice and quantitatively greater in TG mice such that they eliminate differences between adult WT and TG mice. There are implications in these results for understanding the pathogenesis of AD because they suggest that nutrient factors available in the diet during development may profoundly affect the development of disease much later in life.

Disclosure

The authors declare that they have no conflicts of interest with the contents of this article.

Acknowledgments

This work was supported by grants from the NIH, the Alzheimer's Association, and the American Health Assistance Foundation (to PHA).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.neurobiolaging.2019.03.001>.

References

- Anderson, A.B., Darst, S.A., Robertson, C.R., 1987. Protein adsorption at polymer surfaces: a study using total internal reflection fluorescence. In: *Proteins at Interfaces*, Unknown. American Chemical Society, pp. 306–323.
- Axelsen, P.H., Komatsu, H., Murray, I.V.J., 2011. Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. *Physiology (Bethesda)* 26, 54–69.
- Axelsen, P.H., Murphy, R.C., 2010. Quantitative analysis of phospholipids containing arachidonate and docosahexaenoate chains in microdissected regions of mouse brain. *J. Lipid Res.* 51, 660–671.
- Axelsen, P.H., Murphy, R.C., Igarashi, M., Rapoport, S.I., 2016. Increased omega6-containing phospholipids and primary Omega6 oxidation products in the brain tissue of rats on an omega3-deficient diet. *PLoS One* 11, e0164326.
- Ballabriga, A., Martinez, M., 1978. Chemical study on development of human forebrain and cerebellum during brain growth spurt period. 2. Phosphoglyceride fatty-acids. *Brain Res.* 159, 363–370.
- Calon, F., Cole, G., 2007. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. *Prostaglandins Leukot. Essent. Fatty Acid* 77, 287–293.
- Calon, F., Lim, G.P., Yang, F.S., Morihara, T., Teter, B., Ubeda, O., Rostaing, P., Triller, A., Salem, N., Ashe, K.H., Frautschi, S.A., Cole, G.M., 2004. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. *Neuron* 43, 633–645.
- Cao, Y., Tao, J.Q., Bates, S.R., Beers, M.F., Haczk, A., 2004. IL-4 induces production of the lung collectin surfactant protein-D. *J. Allergy. Clin. Immunol.* 113, 439–444.
- Chen, H.F., Su, H.M., 2013. Exposure to a maternal n-3 fatty acid-deficient diet during brain development provokes excessive hypothalamic-pituitary-adrenal axis responses to stress and behavioral indices of depression and anxiety in male rat offspring later in life. *J. Nutr. Biochem.* 24, 70–80.
- Chu, J., Zhuo, J.M., Pratico, D., 2012. Transcriptional regulation of beta secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. *Ann. Neurol.* 71, 57–67.
- Connor, W.E., Neuringer, M., Lin, D.S., 1990. Dietary-effects on brain fatty-acid composition - the reversibility of N-3 fatty-acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus-monkeys. *J. Lipid Res.* 31, 237–247.
- Dobbing, J., Sands, J., 1979. Comparative aspects of the brain growth spurt. *Early Hum. Dev.* 3, 79–83.
- Ellis, G., Fang, E., Maheshwari, M., Roltsch, E., Holcomb, L., Zimmer, D., Martinez, D., Murray, I.V.J., 2010. Lipid oxidation and modification of amyloid-beta (A β) in vitro and in vivo. *J. Alzheimers Dis.* 22, 593–607.
- Freund-Levi, Y., Basun, H., Cederholm, T., Faxen-Irving, G., Garlind, A., Grut, M., Vedin, I., Palmblad, J., Wahlund, L.O., Eriksdotter-Jonhagen, M., 2008. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. *Int. J. Geriatr. Psychiatry* 23, 161–169.

- Furman, R., Lee, J.V., Axelsen, P.H., 2018. Analysis of eicosanoid oxidation products in Alzheimer brain by LC-MS with uniformly ¹³C-labeled internal standards. *Free Radic. Biol. Med.* 118, 108–118.
- Furman, R., Murray, I.V.J., Schall, H.E., Liu, Q., Ghiwot, Y., Axelsen, P.H., 2016. Amyloid plaque-associated oxidative degradation of uniformly radiolabeled arachidonic acid. *ACS Chem. Neurosci.* 7, 367–377.
- Giannopoulos, P.F., Joshi, Y.B., Chu, J., Pratico, D., 2013. The 12–15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo. *Aging Cell* 12, 1082–1090.
- Green, P., Glzman, S., Kamensky, B., Yavin, E., 1999. Developmental changes in rat brain membrane lipids and fatty acids: the preferential prenatal accumulation of docosahexaenoic acid. *J. Lipid Res.* 40, 960–966.
- Green, P., Yavin, E., 1996. Fatty acid composition of late embryonic and early postnatal rat brain. *Lipids* 31, 859–865.
- Groeger, A.L., Cipollina, C., Cole, M.P., Woodcock, S.R., Bonacci, G., Rudolph, T.K., Rudolph, V., Freeman, B.A., Schopfer, F.J., 2010. Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. *Nat. Chem. Biol.* 6, 433–441.
- Gruber, F., Ornelas, C.M., Karner, S., Narzt, M.S., Nagelreiter, I.M., Gschwandtner, M., Bochkov, V., Tschachler, E., 2015. Nrf2 deficiency causes lipid oxidation, inflammation, and matrix-protease expression in DHA-supplemented and UVA-irradiated skin fibroblasts. *Free Radic. Biol. Med.* 88, 439–451.
- Heaton, A.E., Meldrum, S.J., Foster, J.K., Prescott, S.L., Simmer, K., 2013. Does docosahexaenoic acid supplementation in term infants enhance neurocognitive functioning in infancy? *Front Hum. Neurosci.* 7, 774.
- Hibbeln, J.R., Davis, J.M., Steer, C., Emmett, P., Rogers, I., Williams, C., Golding, J., 2007. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. *Lancet* 369, 578–585.
- Hunt, C.A., Schenker, L.J., Kennedy, M.B., 1996. PSD-95 is associated with the post-synaptic density and not with the presynaptic membrane at forebrain synapses. *J. Neurosci.* 16, 1380.
- Husted, K.S., Bouzinova, E.V., 2016. The importance of n-6/n-3 fatty acids ratio in the major depressive disorder. *Medicina (Kaunas)* 52, 139–147.
- Issa, A.M., Mojica, W.A., Morton, S.C., Traina, S., Newberry, S.J., Hilton, L.G., Garland, R.H., MacLean, C.H., 2006. The efficacy of omega-3 fatty acids on cognitive function in aging and dementia: a systematic review. *Dement. Geriatr. Cogn. Discord.* 21, 88–96.
- Kim, D.H., Lim, H., Lee, D., Choi, S.J., Oh, W., Yang, Y.S., Oh, J.S., Hwang, H.H., Jeon, H.B., 2018. Thrombospondin-1 secreted by human umbilical cord blood-derived mesenchymal stem cells rescues neurons from synaptic dysfunction in Alzheimer's disease model. *Sci. Rep.* 8, 354.
- Kodas, E., Vancassel, S., Lejeune, B., Guilloteau, D., Chalou, S., 2002. Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage. *J. Lipid Res.* 43, 1209–1219.
- Lauret, E., Pratico, D., 2017. Effect of canola oil consumption on memory, synapse and neuropathology in the triple transgenic-*Amo* model of Alzheimer's disease. *Sci. Rep.* 7, 17134.
- Lauritzen, L., Brambilla, P., Mazzocchi, A., Harslof, L.B.S., Ciappolino, V., Agostoni, C., 2016. DHA effects in brain development and function. *Nutrients* 8, 6.
- Lee, J.V., Furman, R., Axelsen, P.H., 2017. Biosynthesis of uniformly labeled C-13- and C-14-arachidonic acid in *Mortierella alpina*. *Bioresour. Technol.* 227, 142–146.
- Lee, S.H., Blair, I.A., 2000. Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation. *Chem. Res. Toxicol.* 13, 698–702.
- Leonardi, F., Attorri, L., Di Benedetto, R., Di Biase, A., Sanchez, M., Nardini, M., Salvati, S., 2005. Effect of arachidonic, eicosapentaenoic and docosahexaenoic acids on the oxidative status of C6 glioma cells. *Free Radic. Res.* 39, 865–874.
- Lim, G.P., Calon, F., Morihara, T., Yang, F.S., Teter, B., Ubeda, O., Salem, N., Frautschi, S.A., Cole, G.M., 2005. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. *J. Neurosci.* 25, 3032–3040.
- Lin, D., Lee, H.G., Liu, Q., Perry, G., Smith, M.A., Sayre, L.M., 2005. 4-oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. *Chem. Res. Toxicol.* 18, 1219–1231.
- Lozada, L.E., Desai, A., Kevala, K., Lee, J.W., Kim, H.Y., 2017. Perinatal brain docosahexaenoic acid concentration has a lasting impact on cognition in mice. *J. Nutr.* 147, 1624–1630.
- Maekawa, M., Watanabe, A., Iwayama, Y., Kimura, T., Hamazaki, K., Balan, S., Ohba, H., Hisano, Y., Nozaki, Y., Ohnishi, T., Toyoshima, M., Shimamoto, C., Iwamoto, K., Bundo, M., Osumi, N., Takahashi, E., Takashima, A., Yoshikawa, T., 2017. Polyunsaturated fatty acid deficiency during neurodevelopment in mice models the prodromal state of schizophrenia through epigenetic changes in nuclear receptor genes. *Transl. Psychiatry* 7.
- Mariani, M.M., Malm, T., Lamb, R., Jay, T.R., Neilson, L., Casali, B., Medarametla, L., Landreth, G.E., 2017. Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease. *Sci. Rep.* 7, 42270.
- Martinez, M., Mougan, I., 1998. Fatty acid composition of human brain phospholipids during normal development. *J. Neurochem.* 71, 2528–2533.
- Mathai, M.L., Soueid, M., Chen, N., Jayasooriya, A.P., Sinclair, A.J., Wlodek, M.E., Weisinger, H.S., Weisinger, R.S., 2004. Does perinatal omega-3 polyunsaturated fatty acid deficiency increase appetite signaling? *Obes. Res.* 12, 1886–1894.
- Miller, L.R., Jorgensen, M.J., Kaplan, J.R., Seeds, M.C., Rahbar, E., Morgan, T.M., Welborn, A., Chilton, S.M., Gillis, J., Hester, A., Rukstalis, M., Sergeant, S., Chilton, F.H., 2016. Alterations in levels and ratios of n-3 and n-6 polyunsaturated fatty acids in the temporal cortex and liver of vervet monkeys from birth to early adulthood. *Physiol. Behav.* 156, 71–78.
- Moriguchi, T., Loewke, J., Garrison, M., Catalan, J.N., Salem, N., 2001. Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver, and serum. *J. Lipid Res.* 42, 419–427.
- Morse, N.L., 2012. Benefits of docosahexaenoic acid, folic acid, vitamin D and iodine on foetal and infant brain development and function following maternal supplementation during pregnancy and lactation. *Nutrients* 4, 799–840.
- Neuman, K.M., Molina-Campos, E., Musial, T.F., Price, A.L., Oh, K.J., Wolke, M.L., Buss, E.W., Scheff, S.W., Mufson, E.J., Nicholson, D.A., 2015. Evidence for Alzheimer's disease-linked synapse loss and compensation in mouse and human hippocampal CA1 pyramidal neurons. *Brain Struct. Funct.* 220, 3143–3165.
- Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L.J., Berry, R., Vassar, R., 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J. Neurosci.* 26, 10129–10140.
- Ozias, M.K., Carlson, S.E., Levant, B., 2007. Maternal parity and diet (n-3) polyunsaturated fatty acid concentration influence accretion of brain phospholipid docosahexaenoic acid in developing rats. *J. Nutr.* 137, 125–129.
- Pallast, S., Arai, K., Wang, X.Y., Lo, E.H., van Leyen, K., 2009. 12/15-Lipoxygenase targets neuronal mitochondria under oxidative stress. *J. Neurochem.* 111, 882–889.
- Pauter, A.M., Trattner, S., Gonzalez-Bengtsson, A., Talamonti, E., Asadi, A., Dethlefsen, O., Jacobsson, A., 2017. Both maternal and offspring Elov2 genotypes determine systemic DHA levels in perinatal mice. *J. Lipid Res.* 58, 111–123.
- Plourde, M., Fortier, M., Vandal, M., Tremblay-Mercier, J., Freemantle, E., Begin, M., Pifferi, F., Cunnane, S.C., 2007. Unresolved issues in the link between docosahexaenoic acid and Alzheimer's disease. *Prostaglandins Leukot. Essent. Fatty Acid* 77, 301–308.
- Quinn, J.F., Raman, R., Thomas, R.G., Yurko-Mauro, K., Nelson, E.B., Van Dyck, C., Galvin, J.E., Emond, J., Jack, C.R., Weiner, M., Shinto, L., Aisen, P.S., 2010. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *J. Am. Med. Assoc.* 304, 1903–1911.
- Ramsey, C.P., Glass, C.A., Montgomery, M.B., Lindl, K.A., Ritson, G.P., Chia, L.A., Hamilton, R.L., Chu, C.T., Jordan-Sciutto, K.L., 2007. Expression of Nrf2 in neurodegenerative diseases. *J. Neuropathol. Exp. Neurol.* 66, 75–85.
- Rapoport, S.I., Igarashi, M., Gao, F., 2010. Quantitative contributions of diet and liver synthesis to docosahexaenoic acid homeostasis. *Prostaglandins Leukot. Essent. Fatty Acid* 82, 273–276.
- Sakayori, N., Kikkawa, T., Tokuda, H., Kiryu, E., Yoshizaki, K., Kawashima, H., Yamada, T., Arai, H., Kang, J.X., Katagiri, H., Shibata, H., Innis, S.M., Arita, M., Osumi, N., 2016. Maternal dietary imbalance between omega-6 and omega-3 polyunsaturated fatty acids impairs neocortical development via epoxy metabolites. *Stem Cells* 34, 470–482.
- Salvati, S., Campeggi, L.M., Benedetti, P.C., Difelice, M., Gentile, V., Nardini, M., Tomassi, G., 1993. Effects of dietary oils on fatty-acid composition and lipid-peroxidation of brain membranes (myelin and synaptosomes) in rats. *J. Nutr. Biochem.* 4, 346–350.
- Savioz, A., Leuba, G., Vallet, P.G., 2014. A framework to understand the variations of PSD-95 expression in brain aging and in Alzheimer's disease. *Ageing Res. Rev.* 18, 86–94.
- Schebb, N.H., Ostermann, A.I., Yang, J., Hammock, B.D., Hahn, A., Schuchardt, J.P., 2014. Comparison of the effects of long-chain omega-3 fatty acid supplementation on plasma levels of free and esterified oxylipins. *Prostaglandins Other Lipid Mediat.* 113, 21–29.
- Shao, C.Y., Mirra, S.S., Sait, H.B.R., Sacktor, T.C., Sigurdsson, E.M., 2011. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced A beta and tau pathology in transgenic mouse models of Alzheimer's disease. *Acta Neuropathol.* 122, 285–292.
- Simopoulos, A.P., 2016. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. *Nutrients* 8, 128.
- Sinclair, A.J., Crawford, M.A., 1972. Accumulation of arachidonate and docosahexaenoate in developing rat-brain. *J. Neurochem.* 19, 1753–1758.
- Stiles, J., Jernigan, T.L., 2010. The basics of brain development. *Neuropsychol. Rev.* 20, 327–348.
- Tang, M.M., Zhang, M., Cai, H.L., Li, H.D., Jiang, P., Dang, R.L., Liu, Y.P., He, X., Xue, Y., Cao, L.J., Wu, Y.Q., 2016. Maternal diet of polyunsaturated fatty acid altered the cell proliferation in the dentate gyrus of hippocampus and influenced glutamatergic and serotonergic systems of neonatal female rats. *Lipids Health Dis.* 15, 71.
- Thomas, M.H., Paris, C., Magnien, M., Colin, J., Pelleieux, S., Coste, F., Escanye, M.C., Pillot, T., Olivier, J.L., 2017. Dietary arachidonic acid increases deleterious effects of amyloid-beta oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA(2) balance. *Alzheimers Res. Ther.* 9, 69.
- Weiser, M.J., Butt, C.M., Mohajeri, M.H., 2016a. Docosahexaenoic acid and cognition throughout the lifespan. *Nutrients* 8, 99.
- Weiser, M.J., Mucha, B., Denheyer, H., Atkinson, D., Schanz, N., Vassiliou, E., Benno, R.H., 2016b. Dietary docosahexaenoic acid alleviates autistic-like behaviors resulting from maternal immune activation in mice. *Prostaglandins Leukot. Essent. Fatty Acid* 106, 27–37.

- Won, S., Levy, J.M., Nicoll, R.A., Roche, K.W., 2017. MAGUKs: multifaceted synaptic organizers. *Curr. Opin. Neurobiol.* 43, 94–101.
- Xiao, Y., Huang, Y., Chen, Z.Y., 2005. Distribution, depletion and recovery of docosahexaenoic acid are region-specific in rat brain. *Br. J. Nutr.* 94, 544–550.
- Xie, H., Hou, S., Jiang, J., Sekutowicz, M., Kelly, J., Bacskai, B.J., 2013. Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. *Proc. Natl. Acad. Sci. U. S. A.* 110, 7904–7909.
- Yavin, E., Himovichi, E., Eilam, R., 2009. Delayed cell migration in the developing rat brain following maternal omega 3 Alpha linolenic acid dietary deficiency. *Neuroscience* 162, 1011–1022.
- Youyou, A., Durand, G., Pascal, G., Piciotti, M., Dumont, O., Bourre, J.M., 1986. Recovery of altered fatty-acid composition induced by A diet devoid of N-3 fatty-acids in myelin, synaptosomes, mitochondria, and microsomes of developing rat-brain. *J. Neurochem.* 46, 224–228.
- Zhang, M.J., Wang, S.P., Mao, L.L., Leak, R.K., Shi, Y.J., Zhang, W.T., Hu, X.M., Sun, B.L., Cao, G.D., Gao, Y.Q., Xu, Y., Chen, J., Zhang, F., 2014. Omega-3 fatty acids protect the brain against ischemic injury by activating Nrf2 and upregulating heme oxygenase 1. *J. Neurosci.* 34, 1903–1915.
- Zhang, W.H., Liu, J.Y., Xu, G.Z., Yuan, Q., Sayre, L.M., 2003. Model studies on protein side chain modification by 4-oxo-2-nonenal. *Chem. Res. Toxicol.* 16, 512–523.